Positions

Associate Professor of Medicine in the School of Medicine

2021 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2010 School of Medicine

Education

M.D., University of North Carolina, Chapel Hill 2004

2004 University of North Carolina, Chapel Hill

, The University of Chicago, INTERNAL MEDICINE 2004 - 2007

2007 The University of Chicago

, The University of Chicago, HEMATOLOGY/ONCOLOGY 2007 - 2010

2010 The University of Chicago

Clinical Trials

Dapansutrile Plus Pembrolizumab in Melanoma (DREAM)

Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma

IDE196-009

IDEAYA: (Melanoma with GNAQ/11 Mutations or PRKC Fusions)

Fianlimab + Cemiplimab vs Pembrolizumab in Resectable Melanoma

Load More

Publications, Grants & Awards

• Grants (39)
• Academics Articles (121)
• Conference Pages (23)
• Book Sections (1)

Showing 1 - 5 of 39

A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma

2025-2030Linnaeus Therapeutics, Inc.

A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma R3767-ONC-2208

2024-2029Regeneron Pharmaceuticals, Inc.

Replimune RP2-202: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naive Adult Patients with Inoperab

2024-2029Replimune, Inc.

IDE196-002

2023-2028IDEAYA Biosciences

(Neo)adjuvant IDE196 in patients with localized ocular melanoma [DAR-UM- 09] IDE196

2023-2028IDEAYA Biosciences

DCI Centers, Cancer Types & Labs

Duke Center for Brain and Spine Metastasis

Melanoma and Advanced Skin Cancers

Offices & Contact

30 Duke Medicine Circle
Durham, NC
27710

DUMC 3198
Durham, NC
27710